PT  - JOURNAL ARTICLE
AU  - Jonathan A. Ledermann
AU  - Christian Marth
AU  - Mark S. Carey
AU  - Michael Birrer
AU  - David D.L. Bowtell
AU  - Stan Kaye
AU  - Iain McNeish
AU  - Amit Oza
AU  - Giovanni Scambia
AU  - Gordon Rustin
AU  - Frederick B. Stehman
AU  - David Gershenson
AU  - Gillian Thomas
AU  - Els Berns
AU  - Antonio Casado
AU  - Nelleke Ottevanger
AU  - Felix Hilpert
AU  - Byoung-Gie Kim
AU  - Aikou Okamoto
AU  - Monica Bacon
AU  - Henry Kitchener
AU  - Gavin C.E. Stuart
TI  - Role of Molecular Agents and Targeted Therapy in Clinical Trials for Women With Ovarian Cancer
AID  - 10.1097/IGC.0b013e31821b2669
DP  - 2011 Apr 01
TA  - International Journal of Gynecologic Cancer
PG  - 763--770
VI  - 21
IP  - 4
4099  - http://ijgc.bmj.com/content/21/4/763.short
4100  - http://ijgc.bmj.com/content/21/4/763.full
SO  - Int J Gynecol Cancer2011 Apr 01; 21
AB  - There is now a greater understanding of the molecular pathways in ovarian cancer, and using this knowledge, a large number of new therapeutic agents can be tested. The success of these drugs will depend on selecting drugs that target known key dysfunctional molecular pathways. To make best use of these compounds, prognostic and predictive biomarkers need to be identified. Novel methods of assessment such as functional imaging need to be developed as additional biological end points to evaluate these therapies. Promising antitumor activity has been observed with some drugs, and careful consideration is needed to determine in what circumstances new agents, such as antiangiogenic compounds, could be considered as a standard therapy. These areas were discussed at the 4th Ovarian Cancer Consensus Conference.